{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:47Z","timestamp":1791410807162,"version":"4.3.3"},"reference-count":71,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) are at the forefront of treating the global health crisis of diabetes mellitus (DM) and obesity. However, the demand for GLP\u20101 RAs has far outstripped its supply and comes with a high monthly cost. Thus, the development of GLP\u20101 RA biosimilars can potentially address these barriers by providing greater access to medications that provide clinical outcomes similar to those of the reference products. A narrative review was conducted to examine the current and future developments for GLP\u20101 RA biosimilars. Liraglutide and semaglutide are the predominant GLP\u20101 RAs being investigated for the development of biosimilars. Preliminary liraglutide biosimilar comparisons to reference liraglutide have demonstrated similar clinical efficacy and safety profiles. Semaglutide and beinaglutide biosimilars are currently under investigation as well. With the growing popularity of GLP\u20101 RAs, accessibility and affordability remain a challenge as monthly costs without insurance for liraglutide, semaglutide and tirzepatide are $1418, $892, and $974 respectively. This trend negatively impacts patients with obesity and DM as well as patients who can utilize it for off\u2010label indications for conditions that benefit from weight loss such as obstructive sleep apnoea and non\u2010alcoholic fatty liver disease. A substantial number of pharmaceutical and healthcare companies worldwide are conducting clinical trials on their GLP\u20101 RA biosimilars. Preliminary results from liraglutide biosimilars are promising, and several semaglutide biosimilars are currently being investigated. Future research should focus on conducting comparative head\u2010to\u2010head trials to determine the clinical outcomes between biosimilars and reference products.<\/jats:p>","DOI":"10.1111\/dom.16110","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T23:28:04Z","timestamp":1733786884000},"page":"1113-1122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["An exploratory analysis of glucagon\u2010like peptide\u20101 (\n                    <scp>GLP<\/scp>\n                    \u20101) agonists and biosimilars: A literature review"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5412-8551","authenticated-orcid":false,"given":"Jimmy","family":"Wen","sequence":"first","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Razick","sequence":"additional","affiliation":[{"name":"Department of Psychology University of California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"How\u2010Volkman","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Bernstein","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Nadora","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Truong","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Razick","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzammil","family":"Akhtar","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Karabala","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldo","family":"Frezza","sequence":"additional","affiliation":[{"name":"College of Medicine California Northstate University College of Medicine  Elk Grove California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2004"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666230413094200"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2022_581"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155217"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2130760"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15386"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010024\u201003896\u2010z"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728"},{"key":"e_1_2_7_10_1","unstructured":"CollinsL CostelloRA.Glucagon\u2010like peptide\u20101 receptor agonists. In: StatPearls. StatPearls.2024. Accessed September 5 2024https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23725"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22\u2010S008"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.3.276"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd23\u20100023"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.861"},{"key":"e_1_2_7_17_1","unstructured":"VermaK.What a string of semaglutide biosimilars could mean for mainland China. Clarivate.2024. Accessed September 22 2024https:\/\/clarivate.com\/blog\/what-a-string-of-semaglutide-biosimilars-could-mean-for-mainland-china\/"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010023\u201000619\u20100"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100122"},{"issue":"9","key":"e_1_2_7_21_1","first-page":"498","article-title":"Liraglutide (victoza): the first once\u2010daily incretin mimetic injection for type\u20102 diabetes","volume":"35","author":"Jackson SH","year":"2010","journal-title":"P T"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.610880"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13374"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122653"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756\u2010185X.13951"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010023\u201001462\u2010w"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.111034"},{"key":"e_1_2_7_28_1","unstructured":"FengJ.Ozempic craze hits China as first GLP\u20101 weight\u2010loss drug is greenlighted. The China Project.2023. Accessed September 22 2024https:\/\/thechinaproject.com\/2023\/07\/07\/ozempic-craze-hits-china-as-first-glp-1-weight-loss-drug-is-greenlighted\/"},{"key":"e_1_2_7_29_1","unstructured":"Glenmark Pharmaceuticals Ltd.Glenmark Is the First to Launch Biosimilar of Popular Anti\u2010Diabetic Drug Liraglutide in India. PR Newswire.2024. Accessed September 22 2024https:\/\/www.prnewswire.com\/in\/news-releases\/glenmark-is-the-first-to-launch-biosimilar-of-popular-anti-diabetic-drug-liraglutide-in-india-302025148.html"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203717666160226144618"},{"key":"e_1_2_7_31_1","volume-title":"StatPearls","author":"Padda IS","year":"2023"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.12.1234"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.15217"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14522"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14965"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12030094"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd16\u20100072"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S470826"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001601\u20102"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3033"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3180"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1219735"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010023\u201000584\u20108"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23\u20101911"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40629\u2010020\u201000126\u20106"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44670"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.02484"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3474"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.17886"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16290"},{"key":"e_1_2_7_54_1","unstructured":"SilverA BurgerL.Drugmaker seeks approval for China's first biosimilar Ozempic. Reuters.com2024. Accessed September 22 2024https:\/\/www.reuters.com\/business\/healthcare\u2010pharmaceuticals\/chinas\u2010first\u2010biosimilar\u2010ozempic\u2010drug\u2010applies\u2010approval\u20102024\u201004\u201003\/"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586\u2010024\u201002044\u2010x"},{"key":"e_1_2_7_56_1","unstructured":"Reuters.India study estimates 11% of population is diabetic.2023. Accessed September 22 2024https:\/\/www.reuters.com\/world\/india\/india\u2010study\u2010estimates\u201011\u2010population\u2010is\u2010diabetic\u20102023\u201006\u201009\/#:~:text=ICMR%2C%20which%20funded%20the%20study Diabetes%20Federation%20%2C%20opens%20new%20tab"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2021.84669"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14493"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00356\u2010X"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.01436"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28280"},{"key":"e_1_2_7_63_1","unstructured":"PutkaS.Diabetes patients also struggle to access GLP\u20101 agonists. MedpageToday.2023. Accessed September 22 2024https:\/\/www.medpagetoday.com\/special-reports\/features\/102773"},{"key":"e_1_2_7_64_1","unstructured":"Concerns with Semaglutide and Other GLP\u20101 Receptor Agonists.Alabama Board of Medical Examiners & Medical Licensure Commission. Accessed September 22 2024https:\/\/www.albme.gov\/press\u2010release\/concerns\u2010with\u2010semaglutide\u2010and\u2010other\u2010glp\u20101\u2010receptor\u2010agonists"},{"key":"e_1_2_7_65_1","unstructured":"FDA Drug Shortages.Fda.govhttps:\/\/dps.fda.gov\/drugshortages.Accessed September 22 2024"},{"key":"e_1_2_7_66_1","unstructured":"LipanovicD.GLP\u20101 receptor agonist shortage expected to continue for all of 2024. The Pharmaceutical Journal.2024. Accessed September 22 2024https:\/\/pharmaceutical\u2010journal.com\/article\/news\/glp\u20101\u2010receptor\u2010agonist\u2010shortage\u2010expected\u2010to\u2010continue\u2010for\u2010all\u2010of\u20102024"},{"key":"e_1_2_7_67_1","unstructured":"Our response to serious supply issues of drugs for people with type 2 diabetes. Diabetes UK.2024. Accessed September 22 2024https:\/\/www.diabetes.org.uk\/about\u2010us\/news\u2010and\u2010views\/our\u2010response\u2010serious\u2010supply\u2010issues\u2010drugs\u2010people\u2010living\u2010type\u20102\u2010diabetes"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26438"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004309"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2362450"},{"issue":"8","key":"e_1_2_7_71_1","first-page":"469","article-title":"The economics of biosimilars","volume":"6","author":"Blackstone EA","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2017.11929552"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.16110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:51:29Z","timestamp":1771059089000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/dom.16110"],"URL":"https:\/\/doi.org\/10.1111\/dom.16110","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16110\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"2024-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}